Evidence map›Paper›PMID 36937046›Full record

ArticleFrontiers in molecular neuroscience2023

Serum miRNA modulations indicate changes in retinal morphology.

Riemke Aggio-Bruce, Ulrike Schumann, Adrian V Cioanca, Fred K Chen, Samuel McLenachan, Rachael C Heath Jeffery, Shannon Das, Riccardo Natoli

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Riemke Aggio-BruceThe John Curtin School of Medical Research, The Australian National University, Acton, ACT, Australia.
Ulrike SchumannThe John Curtin School of Medical Research, The Australian National University, Acton, ACT, Australia.
Adrian V CioancaThe John Curtin School of Medical Research, The Australian National University, Acton, ACT, Australia.
Fred K ChenCentre of Ophthalmology and Visual Science, The University of Western Australia, Perth, WA, Australia.
Samuel McLenachanCentre of Ophthalmology and Visual Science, The University of Western Australia, Perth, WA, Australia.
Rachael C Heath JefferyCentre of Ophthalmology and Visual Science, The University of Western Australia, Perth, WA, Australia.
Shannon DasThe John Curtin School of Medical Research, The Australian National University, Acton, ACT, Australia.
Riccardo NatoliThe John Curtin School of Medical Research, The Australian National University, Acton, ACT, Australia.
Australian National University · AULions Eye Institute · AUUniversity of Sydney · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in the developed world and the detection of its onset and progression are based on retinal morphological assessments. MicroRNA (miRNA) have been explored extensively as biomarkers for a range of neurological diseases including AMD, however differences in experimental design and the complexity of human biology have resulted in little overlap between studies. Using preclinical animal models and clinical samples, this study employs a novel approach to determine a serum signature of AMD progression. Methods: Serum miRNAs were extracted from mice exposed to photo-oxidative damage (PD; 0, 1, 3 and 5 days), and clinical samples from patients diagnosed with reticular pseudodrusen or atrophic AMD. The expression of ~800 miRNAs was measured using OpenArray™, and differential abundance from controls was determined using the HTqPCR R package followed by pathway analysis with DAVID. MiRNA expression changes were compared against quantifiable retinal histological indicators. Finally, the overlap of miRNA changes observed in the mouse model and human patient samples was investigated. Results: Differential miRNA abundance was identified at all PD time-points and in clinical samples. Importantly, these were associated with inflammatory pathways and histological changes in the retina. Further, we were able to align findings in the mouse serum to those of clinical patients. Conclusion: In conclusion, serum miRNAs are a valid tool as diagnostics for the early detection of retinal degeneration, as they reflect key changes in retinal health. The combination of pre-clinical animal models and human patient samples led to the identification of a preliminary serum miRNA signature for AMD. This study is an important platform for the future development of a diagnostic serum miRNA panel for the early detection of retinal degeneration.

Indexed as

age-related macular degenerationdiagnosticsmicroRNAneurodegenerationserum miRNAs

Identifiers

PMID36937046
PMCPMC10020626
OpenAlexW4323044798

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read5
measurements read53
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.